KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Pacira BioSciences (PCRX) EBIAT (2016 - 2025)

Pacira BioSciences has reported EBIAT over the past 16 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put EBIAT at $1.6 million for Q4 2025, down 89.79% from a year ago — trailing twelve months through Dec 2025 was $7.0 million (up 107.07% YoY), and the annual figure for FY2025 was $7.0 million, up 107.07%.
  • EBIAT for Q4 2025 was $1.6 million at Pacira BioSciences, down from $5.4 million in the prior quarter.
  • Over the last five years, EBIAT for PCRX hit a ceiling of $25.8 million in Q2 2023 and a floor of -$143.5 million in Q3 2024.
  • Median EBIAT over the past 5 years was $7.9 million (2022), compared with a mean of $365900.0.
  • Biggest five-year swings in EBIAT: surged 1666.81% in 2023 and later tumbled 1421.29% in 2024.
  • Pacira BioSciences' EBIAT stood at -$5.1 million in 2021, then crashed by 96.92% to -$10.1 million in 2022, then skyrocketed by 346.19% to $24.9 million in 2023, then plummeted by 35.5% to $16.0 million in 2024, then plummeted by 89.79% to $1.6 million in 2025.
  • The last three reported values for EBIAT were $1.6 million (Q4 2025), $5.4 million (Q3 2025), and -$4.8 million (Q2 2025) per Business Quant data.